WuXi Biologics Germany GmbH currently employs a growing team of more than 360 highly skilled people at both sites in Leverkusen and Wuppertal. Dr. Chris Chen, CEO of WuXi Biologics, commented, “The investment in our facilities in Germany will add new capacity and enhance our existing manufacturi...
SHANGHAIand WUPPERTAL,Germany,Dec. 21, 2020/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Bayer, today announced an acquisition deal, under which WuXi Biologics will take over and operate...